National Guidelines For Cardiovascular Diseases Management

Objectives

Kenya’s national cardiovascular disease guidance seeks to prevent and manage cardiovascular disease across the life course, support universal health coverage and affordable care, and help halt and reverse the growing non-communicable disease burden. It aims to standardise evidence-based care across public and private services, improve health and livelihoods, and reduce premature mortality, disability and avoidable economic hardship.[1][2]

• Prevent cardiovascular disease by reducing tobacco use, harmful alcohol use, unhealthy diets, physical inactivity, overweight and obesity, hypertension, diabetes and lipid disorders.[1][3]
• Promote population-wide health promotion alongside risk assessment, early detection, treatment adherence and long-term management for people at elevated cardiovascular risk or with established disease.[1][3]
• Provide guidance for hypertension, ischaemic heart disease, heart failure, rheumatic and congenital heart disease, stroke, venous thromboembolism, infective endocarditis, and cardiovascular conditions associated with diabetes, HIV, chronic kidney disease, pregnancy, older age and athletic participation.[4][5]
• Apply primordial, primary, secondary and tertiary prevention, including screening, surveillance, rehabilitation, palliative care and prevention of recurrence, complications, disability and progression.[3]
• Prioritise hypertension prevention, detection and control as a central means of reducing cardiovascular and kidney complications, with a treatment target below 140/90 mmHg for adults in the general hypertension guidance.[6]
• Strengthen secondary prevention after acute cardiovascular events through rehabilitation, health education, physical activity, dietary advice, medicine adherence, smoking cessation and aggressive management of cardiovascular risk factors.[7]
• Prevent rheumatic fever and rheumatic heart disease through early diagnosis and treatment of Group A streptococcal pharyngitis, anti-inflammatory and supportive care, and sustained secondary prophylaxis to prevent recurrent attacks.[8][9]
• Integrate palliative care throughout cardiovascular illness to relieve physical, psychosocial and spiritual suffering, improve quality of life and prevent avoidable suffering as well as avoidable deaths.[10]

Implementation

Implementation is designed as a standardised, tiered and evidence-based model spanning communities, primary care, county referral facilities and national specialist centres. The Ministry of Health Division of Non-Communicable Diseases, supported by a technical working group and professional, academic, development, county-government, public- and private-sector partners, is associated with coordination and incorporation of the guidance into the standard package of care.[1][2][11]

• Deploy community health volunteers at Tier 1 to assess cardiovascular risk using basic equipment, deliver health education and link households with facilities, with Community Health Extension Workers coordinating their activities.[5]
• Deliver awareness and prevention through posters, vernacular radio, barazas, community education forums, dialogue and action days, alongside counselling on healthy lifestyles and risk-factor control.[5]
• Provide lifestyle advice, blood-pressure and blood-sugar assessment, electrocardiography, lipid and renal-function testing, urinalysis, initial management of hypertension and type 2 diabetes, referral and follow-up at Tiers 2 and 3.[12]
• Provide comprehensive risk assessment, imaging, laboratory assessment, primary and secondary prevention, coordinated referral and follow-up at Tiers 3 and 4, with advanced interventions, cardiac surgery, devices, transplantation and rehabilitation at Tier 4.[12]
• Staff and equip services progressively, from general clinical, nursing, nutrition, laboratory, pharmacy and diagnostic personnel at lower levels to specialist cardiovascular, surgical, anaesthetic, perfusion, pathology and imaging teams at higher levels.[12]
• Harmonise referral pathways and clarify workforce roles within the devolved system so that basic services are available nearer to communities and congestion at county and national referral facilities is reduced.[1]
• Use validated cardiovascular risk assessment, including World Health Organization and International Society of Hypertension AFRO E charts adapted for Kenya, to tailor prevention and treatment according to individual risk.[13]
• Strengthen emergency pathways for acute coronary syndrome and stroke through ambulance coordination, rapid triage, early electrocardiography or brain imaging, specialist consultation, transfer arrangements and appropriately equipped receiving facilities.[14][15]
• Establish condition-specific multidisciplinary care where needed, including anticoagulation clinics for venous thromboembolism, joint cardiology and obstetric review for high-risk pregnancy, cardiac rehabilitation, and holistic palliative-care teams involving patients and families.[16][17][10]
• Support surveillance, research and health information systems, including research on cardiovascular burden, determinants, outcomes and quality of care across counties; the guidance also identifies epidemiological surveillance and data collection for rheumatic fever and rheumatic heart disease services.[18][19]
• Build capacity through training, partnership-building and sustained adequate funding at all governance levels, while recognising that the supplied material does not provide a quantified implementation budget or funding allocation.[1]

Monitoring & Evaluation

Monitoring is principally embedded in clinical assessment, risk stratification, treatment follow-up, referral and surveillance activities rather than in a unified national monitoring and evaluation framework. The supplied material does not specify formal national indicators, reporting schedules, evaluation methods, audit arrangements, surveillance governance or independent accountability bodies for implementation of the cardiovascular disease guidelines.[1][19][11]

• Use cardiovascular risk assessment to guide prevention and treatment, including World Health Organization/International Society of Hypertension AFRO E risk charts, risk categorisation and periodic review of risk profiles. For people with estimated cardiovascular risk above 20%, review risk every three to six months; for risk of 10% to 20%, review every six to 12 months.[13][20]
• Monitor hypertension through accurate, repeated blood-pressure measurement and use blood pressure below 140/90 mmHg as the general treatment-control target. The 2015 STEPS survey identified major gaps in screening, awareness, treatment and control, which are highlighted as important population measures, although no formal reporting structure is defined.[6][21]
• Undertake condition-specific clinical follow-up, including lipid monitoring for statin treatment, renal function and electrolyte monitoring during heart-failure and antihypertensive treatment, anticoagulation monitoring through activated partial thromboplastin time or international normalised ratio testing, and clinical monitoring for medicine adverse effects.[22][23][24][25]
• Apply service-level assessment and time-critical monitoring in acute care, including electrocardiography within 10 minutes for chest pain or acute coronary syndrome, frequent vital-sign monitoring for acute coronary syndrome and stroke, and structured stroke-severity assessment.[26][27][28]
• Use follow-up arrangements across tiers of care, including referral, downward follow-up and continuity of management for cardiovascular disease, hypertension, rheumatic heart disease, congenital heart disease, stroke and heart failure.[12][29][30][31][32]
• Conduct epidemiological surveillance for rheumatic fever and rheumatic heart disease at service levels two through five, supported by data-collection tools, and notify cases to an acute rheumatic fever/rheumatic heart disease register where such a register exists.[30][19]
• Strengthen research on the population and facility burden of priority cardiovascular diseases, determinants, severity, outcomes and quality of care across Kenyan counties.[18]
• Maintain competence for acute coronary syndrome care through staff certification and recertification in basic and advanced cardiac life support; advanced cardiac life support recertification is recommended every five years.[33]
• Integrate routine monitoring into care for priority populations, including annual creatinine, lipid and glucose testing in HIV services where indicated, blood-pressure assessment at every visit for people with type 2 diabetes, serial antenatal cardiovascular assessment, and newborn congenital heart disease screening using auscultation and pulse oximetry.[34][35][17][36]

Costing & Financing

The guideline recognises that cardiovascular disease creates substantial economic pressure through costly diagnosis and management, premature death, lost productivity, catastrophic spending and high out-of-pocket expenditure. It calls for sustained adequate funding, skilled human resources and partnerships, but does not provide an overall budget, costing methodology, financing allocation, funding gap, resource-mobilisation plan or quantified economic assumptions.[1][5]

• Identify sustained adequate funding as a requirement for implementation across levels of governance, alongside workforce capacity and partnerships.[1]
• Recognise that shared ambulances, specialist centres, high-dependency and intensive-care services, catheterisation laboratories, rehabilitation facilities and confidential record-sharing may concentrate scarce expertise and improve resource efficiency for ischaemic heart disease care.[7]
• Provide tiered cardiovascular services requiring progressively greater investments in trained personnel, laboratory capacity, imaging, medicines, consumables, surgical services, interventional cardiology and research capacity, although no cost estimates are supplied.[19]
• Note that the costs of medicines and of attending health-care centres may contribute to antihypertensive non-adherence.[37]
• Recognise that chronic kidney disease and its cardiovascular complications impose major economic burdens on individuals, families and health systems, particularly at advanced stages and through hospitalisation, without supplying monetary estimates.[38]
• Describe selected interventions as economically favourable without quantification: prevention or delay of symptomatic heart failure is characterised as cost-beneficial; sodium and fluid management and patient education may reduce hospital use and costs; cardiac resynchronisation therapy may offer significant cost-benefit for selected patients; and benzathine penicillin G secondary prophylaxis is described as cost-effective at community and population levels.[39][23][40][9]
• Present palliative care as potentially reducing overall disease costs and inpatient days while improving symptom management and quality of life, but without a budget or economic estimate.[10]
• Acknowledge financial and technical support for guideline development from Healthy Heart Africa, the World Health Organization Kenya Country Office and the African Institute for Health and Development.[2]